DHL Expands Healthcare Logistics with CRYOPDP Acquisition
Subscribe to our free newsletter today to keep up-to-date with the latest in supply chain news.
DHL Supply Chain has acquired CRYOPDP, a specialist in temperature-sensitive transport for the life sciences sector. The company, a subsidiary of Cryoport, brings a specialized portfolio that includes time-critical, temperature-controlled logistics.
Operating in 15 countries and handling over 600,000 shipments per year across 135 destinations, CRYOPDP has established itself as a reliable partner in clinical trials and pharmaceutical distribution. According to Grand View Research, the global healthcare logistics market is projected to grow more than 6 percent annually through 2030.
DHL’s life sciences logistics business is growing faster than ever
DHL Supply Chain’s life sciences and healthcare segment generated €5 billion in global revenue in 2024. This growth has been supported by a rising number of clients across pharmaceuticals, medical devices, and clinical research sectors.
In the past few years, DHL has invested more than $400 million in healthcare logistics infrastructure worldwide. A notable $200 million investment was made in the United States to expand capacity for vaccine storage, biologics, and temperature-sensitive pharmaceuticals.
DHL’s Strategy 2030 identifies life sciences logistics as a strategic focus. The company aims to enhance its cold chain services, integrate real-time monitoring technologies, and increase the reliability of last-mile delivery.
CRYOPDP brings global reach and deep clinical expertise to DHL
CRYOPDP has built its business around supporting clinical trials and life sciences shipments under tight regulatory and time constraints. The company works with sponsors, CROs, and laboratories to move materials that are essential to drug development and research.
By acquiring CRYOPDP, DHL gains immediate access to a mature network that spans key healthcare markets in Europe, Asia-Pacific, and Latin America. The operational standards at CRYOPDP, including GDP and ISO certifications, align with DHL’s own compliance framework.
Strategic alliance with Cryoport aims to reshape healthcare logistics
Alongside the acquisition, DHL has entered a multi-year strategic partnership with Cryoport. Known for its cryogenic transport services, Cryoport focuses on cell and gene therapies and other ultra-sensitive biopharma products.
This alliance is structured to support joint innovation in supply chain design, product integrity, and container technology. It will also enable DHL to leverage Cryoport’s storage facilities and cryogenic capabilities, strengthening its global infrastructure.
Clients can expect better visibility, fewer vendor handoffs, and more secure end-to-end shipment management. As personalized medicine becomes more widespread, demand for such integrated and high-reliability logistics services is set to rise sharply.
The addition of CRYOPDP’s cold chain and clinical logistics expertise gives DHL an edge over other global competitors. Companies in biotechnology, pharmaceuticals, and clinical development stand to benefit from more efficient, scalable, and specialized solutions.
CRYOPDP’s expertise accelerates DHL’s expansion into cryogenic and ultra-low temperature transport. The partnership with Cryoport adds innovation in packaging, data monitoring, and risk management, helping clients meet evolving regulatory and scientific demands.
Sources: